Active substance
Tizanidine
- SFDA 8
- US FDA 33
- Health Canada 2
- US price lines 5
- NHS prices 2
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| RELEZIN 2 MG TABLET | 2 mg | Tablet · Oral use | 30 Blister | SAR 14.75 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| RELEZIN 4 MG TABLET | 4 mg | Tablet · Oral use | 30 Blister | SAR 24.20 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| SIRDALUD 2MG TAB | 2 mg | Tablet · Oral use | 30 Blister | SAR 18.75 | NCE · Prescription | Sandoz Pharmaceuticals | Valid |
| SIRDALUD 4MG TAB | 4 mg | Tablet · Oral use | 30 Blister | SAR 30.70 | NCE · Prescription | Sandoz Pharmaceuticals | Valid |
| TILAX 2 MG TABLET | 2 mg | Tablet · Oral use | 30 Blister | SAR 17.80 | Generic · Prescription | RIYADH PHARMA | Valid |
| TILAX 4 MG TABLET | 4 mg | Tablet · Oral use | 30 Blister | SAR 29.15 | Generic · Prescription | RIYADH PHARMA | Valid |
| SIRDALUD 2MG TAB | 2 mg | Tablet · Oral use | 30 Blister | SAR 23.45 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| SIRDALUD 4MG TAB | 4 mg | Tablet · Oral use | 30 Blister | SAR 38.40 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
LOW BACK PAIN; MULTIPLE SCLEROSIS; SPASTICITY
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZANAFLEX | EQ 4MG BASE | tablet · oral | LEGACY | Prescription | 27 Nov 1996 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | DR REDDYS LABS INC | Prescription | 3 Jul 2002 |
| ZANAFLEX | EQ 2MG BASE; EQ 4MG BASE; EQ 6MG BASE | capsule · oral | LEGACY | Prescription | 29 Aug 2002 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | EPIC PHARMA LLC | Prescription | 11 Oct 2002 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | RISING | Prescription | 28 Mar 2003 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | SUN PHARM INDS INC | Prescription | 29 Sep 2003 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | TP ANDA HOLDINGS | Prescription | 20 Oct 2003 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | AUROBINDO PHARMA USA | Prescription | 16 Dec 2003 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | APOTEX | Prescription | 16 Jan 2004 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE; EQ 6MG BASE | capsule · oral | APOTEX INC | Prescription | 3 Feb 2012 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | UNICHEM LABS LTD | Prescription | 28 Nov 2012 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE; EQ 6MG BASE | capsule · oral | ZYDUS PHARMS | Prescription | 3 Mar 2017 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE; EQ 6MG BASE | capsule · oral | JUBILANT GENERICS | Prescription | 4 Aug 2017 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | CADILA | Prescription | 9 Mar 2018 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | ALKEM LABS LTD | Prescription | 25 Jan 2019 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE; EQ 6MG BASE | capsule · oral | INGENUS PHARMS LLC | Prescription | 12 Mar 2019 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE; EQ 6MG BASE | capsule · oral | CADILA PHARMS LTD | Prescription | 26 Mar 2019 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE; EQ 6MG BASE | capsule · oral | ALKEM LABS LTD | Prescription | 27 Mar 2019 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE; EQ 6MG BASE | capsule · oral | ALEMBIC | Prescription | 13 Jan 2020 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE; EQ 6MG BASE | capsule · oral | AUROBINDO PHARMA LTD | Prescription | 24 Mar 2020 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE; EQ 6MG BASE; EQ 8MG BASE | capsule · oral | RUBICON RESEARCH | Prescription | 27 May 2020 |
| TIZANIDINE HYDROCHLORIDE | EQ 4MG BASE; EQ 6MG BASE | capsule · oral | SENORES PHARMS | Prescription | 13 May 2024 |
| TIZANIDINE HYDROCHLORIDE | EQ 2MG BASE; EQ 4MG BASE | tablet · oral | RISING | Prescription | 7 Aug 2024 |
| ONTRALFY | EQ 2MG BASE/5ML | solution · oral | FIDELITY BIOPHARMA | Prescription | 12 Dec 2024 |
| ZANAFLEX | EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | LEGACY | Discontinued | 27 Nov 1996 |
8 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-TIZANIDINE | 02259893 | 4 MG | TABLET · ORAL | APOTEX INC |
| MINT-TIZANIDINE | 02536765 | 4 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | TIZANIDINE HCL 2 MG CAPSULE | $0.09015 | per EA | 23 Sep 2026 |
| US NADAC | TIZANIDINE HCL 2 MG TABLET | $0.0317 | per EA | 23 Sep 2026 |
| US NADAC | TIZANIDINE HCL 4 MG CAPSULE | $0.09672 | per EA | 23 Sep 2026 |
| US NADAC | TIZANIDINE HCL 4 MG TABLET | $0.03306 | per EA | 23 Sep 2026 |
| US NADAC | TIZANIDINE HCL 6 MG CAPSULE | $0.14053 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Tizanidine 2mg tablets | £4.76 | 120 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Tizanidine 4mg tablets | £7.88 | 120 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 22 Nov 2024 ZANAFLEX — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Nov 2024 ZANAFLEX — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.